Loading
Life sciences · Journal article
Cell Death and Disease · November 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Platinum and poly (ADP-ribose) polymerase (PARP) inhibitors are cornerstone therapies for ovarian cancer (OC), and their efficacy relies on homologous recombination deficiency (HRD), leaving more than 50% of HRD-negative OC patients with limited treatment options. This study investigated the epigenetic regulator, Polycomb Repressive Complex 2 (PRC2), as both a potential modulator of homologous recombination (HR) status and a candidate therapeutic target in ovarian cancer. We demonstrated that a triple combination regimen comprising PRC2 inhibitors, cisplatin, and PARP inhibitors induced synthetic lethality in BRCA-wild-type ovarian cancer. Functionally, PRC2 inhibition exacerbated cisplatin-induced DNA double-strand breaks. Further analysis showed that this resulted from compromised HR repair, as evidenced by impaired formation of BRCA1 and RAD51 repair foci. Mechanistically, chromatin-binding proteomics identified the autophagy receptor sequestosome-1 (SQSTM1) as a key downstream effector necessary for PRC2-mediated assembly of repair complexes, where it contributed to PRC2-regulated HR repair through reshaping chromatin ubiquitination. Critically, depletion of SQSTM1 attenuated the HR-promoting function of PRC2. For clinical translation, the synthetic lethality was further validated in patient-derived organoids (PDOs) and patient-derived xenografts (PDXs). Moreover, maintenance therapy combining PRC2 and PARP inhibitors following cisplatin chemotherapy has been identified as an optimal strategy. Collectively, our study revealed a novel PRC2-SQSTM1-HR regulatory axis, established PRC2 inhibition as a promising strategy to sensitize HRD-negative OCs to conventional therapies, and provided a strong mechanistic rationale for a new combination treatment paradigm.